Loading...

ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 2.9 USD -3.33% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

EPIX's intrinsic value estimate is unreliable because it is based only on its DCF value.

The intrinsic value of one EPIX stock under the Base Case scenario is 3.79 USD. Compared to the current market price of 2.9 USD, ESSA Pharma Inc is Undervalued by 24%.

The Intrinsic Value is calculated as the average of the two valuation methods:

EPIX Intrinsic Value
Base Case
3.79 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

EPIX Profitability Score
Profitability Due Diligence

ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative ROIC
Negative ROE
26/100
Profitability
Score

ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

EPIX Solvency Score
Solvency Due Diligence

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Short-Term Liabilities
Long-Term Liabilities
Low D/E
High Altman Z-Score
81/100
Solvency
Score

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
ESSA Pharma Inc

Current Assets 165M
Cash & Short-Term Investments 163M
Receivables 14.6k
Other Current Assets 1.5M
Non-Current Assets 416k
PP&E 156k
Other Non-Current Assets 259k
Current Liabilities 2.9M
Accounts Payable 1.6M
Accrued Liabilities 1.3M
Other Current Liabilities -10
Non-Current Liabilities 48.3k
Other Non-Current Liabilities 48.3k
Efficiency
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
FCF Margin
-6 982%
ROIC
-20%
ROCE
Other

EPIX Capital Structure
ESSA Pharma Inc

Market Capitalization 128M USD
Total Debt 0 USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 51.2M USD
Short-Term Investments 112M USD
Enterprise Value -35.2M USD

Wall St
Price Targets

EPIX Price Targets Summary
ESSA Pharma Inc

There are no price targets for EPIX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

EPIX Competitors
ESSA Pharma Inc

EPIX Suppliers & Customers
ESSA Pharma Inc

Suppliers Map
Customers Map

Ownership

EPIX Insider Trading
Buy and sell transactions by insiders

ESSA Pharma Inc insiders have bought more shares than they have sold in the past 12 months.

During the last 12 months ESSA Pharma Inc insiders bought 11M USD , and sold 876k USD worth of shares. The last transaction was made on Mar 25, 2023 by Parkinson David Ross (Chief Executive Officer), who bought 8k USD worth of EPIX shares.

Sold
0-3
months
0 USD
0
3-6
months
729k USD
1
6-9
months
0 USD
0
9-12
months
147k USD
1
Bought
0-3
months
2
29.6k USD
3-6
months
2
8.3M USD
6-9
months
2
2.7M USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
29.6k USD
29.6k
6 Months
729k USD
8.3M USD
7.6M
9 Months
729k USD
11M USD
10.3M
12 Months
876k USD
11M USD
10.1M
Purchases
11
Sales
6
No transactions found
Why is insider trading important?

Shareholder Return

EPIX Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

EPIX Price
ESSA Pharma Inc

1M 1M
-10%
6M 6M
+65%
1Y 1Y
-54%
3Y 3Y
-25%
5Y 5Y
-26%
Annual Price Range
2.9
52w Low
1.5
52w High
7.94
Price Metrics
Average Annual Return 63.55%
Standard Deviation of Annual Returns 94.13%
Max Drawdown -96%
Shares Statistics
Market Capitalization 128M USD
Shares Outstanding 44 092 400
Percentage of Shares Shorted 1.62%

Company Profile

ESSA Pharma Inc Logo
ESSA Pharma Inc

Country

Canada

Industry

Biotechnology

Market Cap

128M USD

Dividend Yield

0%

Description

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

Contact

BRITISH COLUMBIA
Vancouver
Suite 2600, 595 Burrard Street
+17783310962.0
https://www.essapharma.com/

IPO

-

Employees

30

Officers

Pres, CEO & Director
Dr. David Ross Parkinson M.D.
Chief Financial Officer
Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA
Exec. VP & COO
Mr. Peter A. Virsik M.B.A., M.S.
Chief Medical Officer
Dr. Alessandra Cesano M.D., Ph.D.
Exec.
Nkengyal Barber

See Also

Similar Stocks
What is the Intrinsic Value of one EPIX stock?

The intrinsic value of one EPIX stock under the Base Case scenario is 3.79 USD.

Is EPIX stock undervalued or overvalued?

Compared to the current market price of 2.9 USD, ESSA Pharma Inc is Undervalued by 24%.